Moderna Inc. on Thursday lowered its outlook for full-year revenue.
The Cambridge, Mass.-based pharmaceutical company said it now expects product sales of $15 billion to $18 billion this year. Previously, it had said its advance purchase agreements could account for sales of $20 billion this year.
Some doses for delivery in 2021 have now been shifted to early 2022, the company said. Moderna said it is prioritizing deliveries to low-income countries.
Moderna expects sales of $17 billion to $22 billion in 2022, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.